Baxalta received approval from the FDA for VONVENDI [von Willebrand factor (Recombinant)], the first recombinant treatment for adults with von Willebrand Disease (VWD). VONVENDI is a novel recombinant protein treatment that includes a physiologic distribution of multimer proteins, the most active form of the protein supporting clot formation. The treatment is also the first in the U.S. that contains only trace amounts of Factor VIII (FVIII), offering the flexibility to administer FVIII only w...